AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Theravance Biopharma Receives New Analyst Coverage with Buy Rating and $24 Price Target
ByAinvest
Friday, Jun 20, 2025 3:28 am ET1min read
Theravance Biopharma (TBPH) has received new analyst coverage with a Buy rating from Jones Trading, with a price target of $24.00 per share. This marks a significant development for the company's stock outlook, potentially influencing investor sentiment and market activity. Analysts forecast an average target price of $17.00, with a high estimate of $24.00 and a low estimate of $10.00, indicating an upside of 58.14% from the current price of $10.75.
Theravance Biopharma (TBPH) has received new analyst coverage with a "Buy" rating from Jones Trading, accompanied by a price target of $24.00 per share. This marks a significant development for the company's stock outlook, potentially influencing investor sentiment and market activity. Analysts forecast an average target price of $17.00, with a high estimate of $24.00 and a low estimate of $10.00, indicating an upside of 58.14% from the current price of $10.75.The new rating from Jones Trading underscores the positive outlook for TBPH, which has been in the spotlight for its innovative biopharmaceutical pipeline. Analysts at Jones Trading highlight the company's strong pipeline and potential for growth in the biopharmaceutical sector. The price target reflects the firm's expectations for the stock's performance in the foreseeable future.
This development comes as a boost to TBPH's stock, which has seen fluctuations in recent months. The new analyst coverage is likely to attract the attention of investors, potentially leading to increased market activity and a shift in stock sentiment.
Theravance Biopharma has been making strides in developing novel therapies, and the positive rating from Jones Trading signals confidence in the company's future prospects. Investors should closely monitor this development and consider the implications for TBPH's stock.
References:
[1] https://www.gurufocus.com/news/2934215/sndk-b-of-a-securities-initiates-coverage-with-a-buy-rating-sndk-stock-news
[2] https://www.marketbeat.com/ratings/by-issuer/leerink-swann-stock-recommendations/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet